R&D News | pharmaphorum

News

IPO in wooden blocks on table with green foliage blurred in background

Scribe raises $155m in IPO, as Apnimed pitches for $150m

Gene-editing specialist Scribe becomes the 14th biotech to list on the Nasdaq this year, as sleep apnoea drug developer Apnimed prices its listing.

News

Chris McDonald replaces Vallance as UK science minister

Chris McDonald has been named the next UK Minister for Science, following the resignation of Patrick Vallance last week.

News

Argenx pens $2.2bn deal to buy autoimmune biotech Forte

Netherlands- and Belgium-based argenx has agreed to buy US biotech Forte Bio for up to $2.2bn, bolstering its autoimmune disease pipeline.

News

Ipsen' Bylvay fluffs its lines in biliary atresia trial

Ipsen's IBAT inhibitor Bylvay has failed a trial in biliary atresia, a rare and serious liver disease that affects babies and has limited treatments.

News

Sanofi gives up on amlitelimab in atopic dermatitis

Sanofi has stopped development of anti-OX40L drug amlitelimab in atopic dermatitis, a major blow to what was once viewed as a 'pipeline-in-a-product'.

News

J&J's multiple myeloma duo aces phase 3 trial

Two of Johnson & Johnson's multiple myeloma bispecifics, Tecvayli and Talvey, have dramatically improved survival when used as a second-line regimen.

Scribe raises $155m in IPO, as Apnimed pitches for $150m

Chris McDonald replaces Vallance as UK science minister

Argenx pens $2.2bn deal to buy autoimmune biotech Forte

Ipsen' Bylvay fluffs its lines in biliary atresia trial

Sanofi gives up on amlitelimab in atopic dermatitis

J&J's multiple myeloma duo aces phase 3 trial

Enhertu OK ends 10-year EU gap in frontline breast cancer

Discover a new era of healthcare panel engagement: Grounded ...

News

Editor's Picks